The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
2023
2022
November 24, 2022
The impact of inaction - New publication reveals not all of Canada is on track to meet global hepatitis C elimination goal
November 16, 2022
Canadian migraine sufferers have new treatment option - Health Canada approves UBRELVY® (ubrogepant tablet)
October 13, 2022
For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight
September 27, 2022
XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where previous medical treatments have failed
July 20, 2022
Health Canada approves AbbVie’s RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis
June 22, 2022
MAVIRET® (glecaprevir/pibrentasvir) approved by Health Canada for pediatric patients with chronic hepatitis C
April 27, 2022
Health Canada approves VRAYLAR® (cariprazine) for the treatment of bipolar l disorder and schizophrenia in adults
March 9, 2022
Focusing on the silent thief of sight during World Glaucoma Week
February 24, 2022
AbbVie announces provincial reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for patients with previously untreated chronic lymphocytic leukemia (CLL) in Alberta, Saskatchewan, British Columbia, and Manitoba
February 15, 2022
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology patients
February 10, 2022
AbbVie announces first provincial reimbursements for VENCLEXTA® (venetoclax) in combination with Azacitidine for acute myeloid leukemia patients
2021
October 14, 2021
#WorldSightDay – All eyes encouraged to focus on glaucoma
October 7, 2021
Health Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis
June 7, 2021
Health Canada approves AbbVie’s RINVOQ® (upadacitinib) for the treatment of adults with active psoriatic arthritis
February 24, 2021
AbbVie's SKYRIZI® for the treatment of moderate to severe plaque psoriasis now publicly reimbursed across Canada
2020
December 15, 2020
Health Canada Approves VENCLEXTA® (venetoclax) in combination with azacitidine or low dose cytarabine for untreated Acute Myeloid Leukemia (AML)
November 10, 2020
Health Canada Approves MAVIRET® 8-Week Treatment Duration for Treatment-Naïve Patients with Genotype 3 Compensated Cirrhosis
October 1, 2020
Public coverage of AbbVie’s SKYRIZI® for the treatment of Moderate to Severe Plaque Psoriasis is now available across additional jurisdictions
July 28, 2020
We can eliminate Hepatitis C in Canada by 2030
June 23, 2020
COVID-19 is hurting chronic migraine care in Canada
June 17, 2020
Endometriosis: an invisible disease affecting half a million Canadians
March 11, 2020
AbbVie announces new formulary listings for SKYRIZI® in the treatment of moderate to severe plaque psoriasis
February 26, 2020
VENCLEXTA® with Rituximab, a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL), now reimbursed in British Columbia
February 13, 2020
AbbVie’s SKYRIZI™ Now Listed on the Nova Scotia Formulary for the Treatment of Moderate to Severe Plaque Psoriasis
February 6, 2020
AbbVie's SKYRIZI™ now publicly reimbursed in Ontario, Alberta, Saskatchewan and Quebec for the treatment of moderate to severe plaque psoriasis
January 14, 2020
AbbVie’s MAVIRET® now listed on the Newfoundland and Labrador formulary
2019
October 23, 2019
AbbVie’s Suzanne Campbell recognized by peers
September 25, 2019
VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada
July 25, 2019
AbbVie is committed to the elimination of hepatitis C in Canada by 2030
June 10, 2019
AbbVie’s MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
May 30, 2019
AbbVie’s MAVIRET™ now listed in New Brunswick
April 18, 2019
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
April 11, 2019
AbbVie’s MAVIRET™ now reimbursed in Quebec
April 4, 2019
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
March 22, 2019
British Columbia PharmaCare Lists AbbVie’s Hepatitis C Treatment MAVIRET™ on its Formulary
February 21, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™
February 20, 2019
AbbVie’s HUMIRA® (Adalimumab) approved by Health Canada to treat pediatric patients with chronic non-infectious anterior
2018
October 5, 2018
AbbVie receives Health Canada approval of ORILISSA™ (elagolix) for the treatment of moderate to severe pain associated with endometriosis
September 27, 2018
Health literacy still an issue in Canada
September 25, 2018
AbbVie receives approval from Health Canada for the combination of Venclexta® with Rituximab as a treatment for patients with chronic lymphocytic leukemia
August 14, 2018
Crohn's and Colitis Canada Selects 10 AbbVie IBD Scholarship Recipients
February 22, 2018
Nova Scotians living with Advanced Parkinson’s Disease now have public access to DUODOPA® to manage their disease
February 21, 2018
Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease
2017
October 25, 2017
Nail psoriasis data now part of HUMIRA® label
August 29, 2017
More Canadians have access to HUMIRA® (adalimumab) for the treatment of Ulcerative Colitis (UC)
August 17, 2017
AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes
August 8, 2017
Introducing the 2017 AbbVie IBD Scholarship recipients
June 28, 2017
AbbVie IBD Scholarship expands in celebration of Canada 150
June 7, 2017
ABC Life Literacy Canada engages Canadians to increase their health literacy with ABC Health Matters
